Ignite Creation Date:
2024-05-06 @ 8:31 AM
Last Modification Date:
2024-10-26 @ 12:01 PM
Study NCT ID:
NCT02756429
Status:
COMPLETED
Last Update Posted:
2018-02-22
First Post:
2016-04-27
Brief Title:
Quantification of Endothelial Thrombogenicity in Patients With Atrial Fibrillation
Sponsor:
Hospices Civils de Lyon
Organization:
Hospices Civils de Lyon
Study Overview
Official Title:
None
Status:
COMPLETED
Status Verified Date:
2018-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
REMI-2
Brief Summary:
Atrial fibrillation AF is the most common cardiac arrhythmia Because of its major impact on the general morbidity and risk of stroke AF is a great concern for public health Several mechanisms including endothelial dysfunction and inflammatory processes have been postulated as predisposing factors for AF as well as for stroke
Both clinical and experimental studies highlight inflammation as a predisposing factor for AF and its complications Nevertheless the source of high inflammatory proteins in patients with AF is still unknown We hypothesized that multilevel intracardiac and extracardiac left femoral vein coronary sinus left atrium pulmonary vein measurements of several inflammatory proteins VEGF would help assessing the extent and the source of inflammation in AF patients
The measurement of von Willebrand factor vWF levels in multiple vascular sites would also help to define the site of endothelial dysfunction and of production of this thrombogenic factor
Although AF is associated with an increased risk of stroke the risk is not homogeneous Permanent and persistent AF are associated with similar thromboembolic risk to that of paroxysmal AF
Both clinical and experimental studies highlight inflammation as a predisposing factor for AF and its complications Nevertheless the source of high inflammatory proteins in patients with AF is still unknown We hypothesized that multilevel intracardiac and extracardiac left femoral vein coronary sinus left atrium pulmonary vein measurements of several inflammatory proteins VEGF would help assessing the extent and the source of inflammation in AF patients
The measurement of von Willebrand factor vWF levels in multiple vascular sites would also help to define the site of endothelial dysfunction and of production of this thrombogenic factor
Although AF is associated with an increased risk of stroke the risk is not homogeneous Permanent and persistent AF are associated with similar thromboembolic risk to that of paroxysmal AF
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None